Carbon monoxide poisoning

Normocapnic hyperpnoea

A device which uses the concept of normocapnic hyperpnoea was approved by the US Food and Drug Administration in 2019.[45]US Food and Drug Administration. FDA allows marketing of new device to help treat carbon monoxide poisoning. Mar 2019 [internet publication]. https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-new-device-help-treat-carbon-monoxide-poisoning ​ The device delivers 100% oxygen to the patient, as well as a mixture of oxygen and carbon dioxide, therefore increasing the patient’s respiratory rate and total minute ventilation, and consequently increasing the clearance of carbon monoxide.[46]Takeuchi A, Vesely A, Rucker J, et al. A simple "new" method to accelerate clearance of carbon monoxide. Am J Respir Crit Care Med. 2000 Jun;161(6):1816-9. https://www.atsjournals.org/doi/10.1164/ajrccm.161.6.9907038 http://www.ncbi.nlm.nih.gov/pubmed/10852750?tool=bestpractice.com ​​ The device was approved on the basis of increased elimination of carboxyhemoglobin, versus normobaric oxygen, demonstrated in multiple clinical studies (100 patients), and an absence of device-related complications.[45]US Food and Drug Administration. FDA allows marketing of new device to help treat carbon monoxide poisoning. Mar 2019 [internet publication]. https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-new-device-help-treat-carbon-monoxide-poisoning ​ There are no published studies reporting clinically-relevant outcomes.